Literature DB >> 29778262

Understanding and Addressing Hepatitis C Virus Reinfection Among Men Who Have Sex with Men.

Thomas C S Martin1, Andri Rauch2, Luisa Salazar-Vizcaya2, Natasha K Martin3.   

Abstract

Hepatitis C virus reinfection rates among men who have sex with men are high. Factors associated with infection point to varied sexual and drug-related risks that could be targeted for interventions to prevent infection/reinfection. Modeling indicates that tackling increasing incidence and high reinfection rates requires high levels of hepatitis C virus treatment combined with behavioral interventions. Enhanced testing strategies and prompt retreating of reinfection may be required to promptly diagnosed reinfections. Behavioral interventions studies addressing reinfection are required. Other interventions include traditional harm reduction interventions, adapted behavioral interventions, and interventions to prevent harms related to ChemSex and other risk factors.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hepatitis C virus; Men who have sex with men; Prevention; Reinfection

Mesh:

Year:  2018        PMID: 29778262      PMCID: PMC5973544          DOI: 10.1016/j.idc.2018.02.004

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  41 in total

1.  Chemsex and the city: sexualised substance use in gay bisexual and other men who have sex with men attending sexual health clinics.

Authors:  A Hegazi; M J Lee; W Whittaker; S Green; R Simms; R Cutts; M Nagington; B Nathan; M R Pakianathan
Journal:  Int J STD AIDS       Date:  2016-07-10       Impact factor: 1.359

Review 2.  Sexually transmitted hepatitis C infection: the new epidemic in MSM?

Authors:  Daniel Bradshaw; Gail Matthews; Mark Danta
Journal:  Curr Opin Infect Dis       Date:  2013-02       Impact factor: 4.915

3.  HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe.

Authors:  Patrick Ingiliz; Thomas C Martin; Alison Rodger; Hans-Jürgen Stellbrink; Stefan Mauss; Christoph Boesecke; Mattias Mandorfer; Julie Bottero; Axel Baumgarten; Sanjay Bhagani; Karine Lacombe; Mark Nelson; Jürgen K Rockstroh
Journal:  J Hepatol       Date:  2016-09-17       Impact factor: 25.083

Review 4.  Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy.

Authors:  David L Wyles; Mark S Sulkowski; Douglas Dieterich
Journal:  Clin Infect Dis       Date:  2016-07-15       Impact factor: 9.079

5.  Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.

Authors:  Natasha K Martin; Matthew Hickman; Sharon J Hutchinson; David J Goldberg; Peter Vickerman
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

6.  Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights.

Authors:  Natasha K Martin; Alicia Thornton; Matthew Hickman; Caroline Sabin; Mark Nelson; Graham S Cooke; Thomas C S Martin; Valerie Delpech; Murad Ruf; Huw Price; Yusef Azad; Emma C Thomson; Peter Vickerman
Journal:  Clin Infect Dis       Date:  2016-02-16       Impact factor: 9.079

Review 7.  Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.

Authors:  Bryony Simmons; Jawaad Saleem; Andrew Hill; Richard D Riley; Graham S Cooke
Journal:  Clin Infect Dis       Date:  2016-01-19       Impact factor: 9.079

8.  Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions.

Authors:  Luisa Salazar-Vizcaya; Roger D Kouyos; Cindy Zahnd; Gilles Wandeler; Manuel Battegay; Katharine Elizabeth Anna Darling; Enos Bernasconi; Alexandra Calmy; Pietro Vernazza; Hansjakob Furrer; Matthias Egger; Olivia Keiser; Andri Rauch
Journal:  Hepatology       Date:  2016-10-19       Impact factor: 17.425

9.  HIV-infected men who have sex with men who identify themselves as belonging to subcultures are at increased risk for hepatitis C infection.

Authors:  Amy Matser; Joost Vanhommerig; Maarten F Schim van der Loeff; Ronald B Geskus; Henry J C de Vries; Jan M Prins; Maria Prins; Sylvia M Bruisten
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

10.  Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?

Authors:  Viviane D Lima; Ignacio Rozada; Jason Grebely; Mark Hull; Lillian Lourenco; Bohdan Nosyk; Mel Krajden; Eric Yoshida; Evan Wood; Julio S G Montaner
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

View more
  3 in total

1.  Hepatitis C microelimination among people living with HIV in Taiwan.

Authors:  Guan-Jhou Chen; Shu-Yuan Ho; Li-Hsin Su; Sui-Yuan Chang; Szu-Min Hsieh; Wang-Huei Sheng; Wang-Da Liu; Yu-Shan Huang; Kuan-Yin Lin; Yi-Ting Chen; Yi-Ching Su; Wen-Chun Liu; Hsin-Yun Sun; Chien-Ching Hung
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

2.  The perceived impact of an HIV cure by people living with HIV and key populations vulnerable to HIV in the Netherlands: A qualitative study.

Authors:  Kim A G J Romijnders; Laura de Groot; Sigrid C J M Vervoort; Maartje G J Basten; Berend J van Welzen; Mirjam E Kretzschmar; Peter Reiss; Udi Davidovich; Ganna Rozhnova
Journal:  J Virus Erad       Date:  2022-02-25

3.  Sexually-transmitted hepatitis C virus reinfections among people living with HIV in Taiwan: the emerging role of genotype 6.

Authors:  Guan-Jhou Chen; Hsin-Yun Sun; Sui-Yuan Chang; Li-Hsin Su; Yi-Ting Chen; Szu-Min Hsieh; Wan-Da Liu; Wang-Huei Sheng; Yu-Shan Huang; Kuan-Yin Lin; Yi-Ching Su; Wen-Chun Liu; Chien-Ching Hung
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.